Clinical Trials Logo

Breast Cancer clinical trials

View clinical trials related to Breast Cancer.

Filter by:

NCT ID: NCT04933266 Enrolling by invitation - Breast Cancer Clinical Trials

Subpectoral Plexus Block With Multi-level TPVB for Surgical Anesthesia During Primary Breast Cancer Surgery

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to compare two different doses of local anesthetics (10ml vs 20ml of 0.25% levobupivacaine) for subpectoral plexus block (SPPB) in addition to ultrasound guided multi-level of thoracic paravertebral block (m-TPVB) for surgical anaesthesia for major primary breast cancer surgery.

NCT ID: NCT04929197 Enrolling by invitation - Breast Cancer Clinical Trials

Evaluation of the Feasibility of Developing Personalized Breast Cancer Radiotherapy Assistive Device With 3D Printing

PERSBRA
Start date: April 21, 2016
Phase: N/A
Study type: Interventional

Breast cancer is the most common malignancy among women worldwide. For early stage breast cancer, adjuvant radiotherapy is essential to minimize loco-regional disease recurrence. However, significant portions of the heart and the lungs are exposed to low dose radiation during radiotherapy, which result in stochastic side effects among breast cancer survivors. Inspired by 3D printing technology, we approached this issue with an in-house made PERSonalized BReAst holder system (PERSBRA). PERSBRA is composed of a 3D-printed plastic holder covering the whole breast and an air-filled interface. Its main function is to reproducibly adjust the breast position to decrease heart and lung radiation exposure in tangential fields. Here we propose to measure the performance of PERSBR in terms of radiation dosimetry in 50 patients receiving scheduled whole breast irradiation. For customized PERSBRA, body shape of the patient with or without a bustier corset will be captured with a handheld 3D scanner and input into a 3D printer for PERSBRA design and manufacturing. A participant will receive two more CT scans in addition to the simulation scan with PERSBRA in place before the first and the sixth fractions of irradiation. These images will be analyzed for dosimetric parameters in the presence/absence of PERSBRA as well as position reproducibility. The data will provide proof-of-principle evidence for the clinical utility of PERSBRA and will facilitate its further refinement.

NCT ID: NCT04928014 Enrolling by invitation - Healthy Clinical Trials

Validation of a Tear-based Screening Assay for Breast Cancer

Start date: June 1, 2021
Phase:
Study type: Observational

This study will explore and better understand the value, usage, and benefits of a tear-based screening test for breast cancer as a supplemental tool for screening mammograms. This tear-based screening test was developed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.

NCT ID: NCT04914494 Enrolling by invitation - Breast Cancer Clinical Trials

Cancer Predictive Score on Breast MRI

Start date: January 1, 2021
Phase:
Study type: Observational

Sometimes, breast ultrasound and mammographic can't be diagnose suspsious lesions ( no substratum). So a MRI-guided breast biopsy is perfomed and disclosed ultimately benign lesions. The aim of this retrospective study is to establish a predictive MRI score of occult breast lesions by mammography and ultrasound.

NCT ID: NCT04862078 Enrolling by invitation - Breast Cancer Clinical Trials

Shared Decision Making in Surveillance for Distant Metastasis in Breast Cancer

SMART-FU
Start date: July 6, 2021
Phase: N/A
Study type: Interventional

In this study, clinical impacts of shared decision making between physicians and patients in strategy of surveillance for asymptomatic patients who ended the primary treatments on quality of life would be investigated

NCT ID: NCT04839835 Enrolling by invitation - Breast Cancer Clinical Trials

Anxiety on the First Day of Chemotherapy

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

investigating chemotherapy anxieties

NCT ID: NCT04488614 Enrolling by invitation - Breast Cancer Clinical Trials

Prospective Breast Cancer Biobanking

PBCB
Start date: September 1, 2011
Phase:
Study type: Observational

Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation

NCT ID: NCT04474834 Enrolling by invitation - Breast Cancer Clinical Trials

GENetic Risk Estimation of Breast Cancer Prior to Decisions on Preventive Therapy Uptake, Risk Reducing Surgery or Intensive Imaging Surveillance

GENRE2
Start date: October 17, 2019
Phase:
Study type: Observational

The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS) in addition to the Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer.

NCT ID: NCT04421963 Enrolling by invitation - Breast Cancer Clinical Trials

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

ROSY-O
Start date: August 4, 2020
Phase: Phase 3
Study type: Interventional

The rationale of the ROSY-O study is to continue to provide study treatment for patients who have participated in a parent study with olaparib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator.

NCT ID: NCT04365114 Enrolling by invitation - Breast Cancer Clinical Trials

Patient Outcomes From Second Film-readers and Test Threshold Relaxation in Breast Screening

POSTBOx
Start date: October 1, 2018
Phase:
Study type: Observational

Analysis of women's medical records to understand the impact of previous changes to breast cancer screening (increase from one to two clinicians examining each woman's mammograms, and what proportion of women they recall for further tests)